文献速递贫血与红细胞疾病

海曲泊帕联合环孢素一线治疗非重型再生障碍性贫血的二期多中心试验

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.
PubMed 文献 · Am J Hematol · 2026-01-05

这项前瞻性单臂二期试验纳入54例新诊断非重型再生障碍性贫血成人患者,其中25例为输血依赖型,评估海曲泊帕联合环孢素A一线治疗的疗效与安全性。24周总缓解率为81.5%,输血依赖亚组达88.0%,不良事件多为1-2级且可控,未观察到向MDS或白血病克隆进展。

要点

  • 海曲泊帕联合CsA一线治疗NSAA的24周ORR为81.5%,CR为9.3%。
  • 输血依赖型NSAA亚组ORR更高达88.0%,血液学指标与生活质量显著改善。
  • 治疗延长至24周可提高CR与稳健PR率,不良事件以1-2级为主且可控。

核心结论

  • 海曲泊帕联合环孢素A可作为非重型再生障碍性贫血尤其是输血依赖型患者潜在的一线治疗选择。

研究设计与样本

  • 前瞻性、单臂、多中心二期试验(NCT05660785),纳入54例新诊断非重型再生障碍性贫血成人,其中25例为输血依赖型。

主要发现

  • 24周总缓解率为81.5%(44/54),其中部分缓解72.2%、完全缓解9.3%。
  • 完全缓解与稳健部分缓解合计达46.3%(25/54)。
  • 输血依赖亚组总缓解率为88.0%(22/25),血液学指标与生活质量显著改善。
  • 治疗从16周延长至24周,完全缓解与稳健部分缓解率从24.0%升至44.0%。
  • 初始缓解中位时间6周,稳健部分缓解中位时间14周;不良事件发生率35%,以1-2级为主且可控。

关键数值与推荐

  • 24周总缓解率81.5%(44/54),完全缓解9.3%,部分缓解72.2%。
  • 完全缓解与稳健部分缓解合计46.3%(25/54)。
  • 输血依赖亚组总缓解率88.0%(22/25)。
  • 16周至24周完全缓解与稳健部分缓解率由24.0%升至44.0%。

临床怎么用

  • 对非重型再生障碍性贫血患者,可考虑海曲泊帕联合环孢素A作为一线方案,尤其适用于输血依赖型患者。
  • 治疗16周未达稳健缓解者可延长至24周以评估进一步获益。

局限性

  • 单臂设计缺乏对照,样本量54例有限,结论需随机对照试验验证。
  • 随访期间未观察到向骨髓增生异常综合征或白血病克隆进展,但长期安全性需更长时间随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies. Thrombopoietin receptor agonists (TPO-RAs) have shown satisfying outcomes in severe aplastic anemia (SAA), but data on their frontline use in NSAA remain scarce. We enrolled 54 adults with newly diagnosed NSAA, including 25 with transfusion-dependent NSAA (TD-NSAA) in the prospective, single-arm Phase 2 trial (NCT05660785) to evaluate the efficacy and safety of hetrombopag, an oral TPO-RA, in combination with CsA. At 24 weeks, the overall response rate (ORR) was 81.5% (44/54), comprising 72.2% partial responses and 9.3% complete responses (CRs). Notably, CR and robust partial response (robust PR) were achieved in 46.3% (25/54) of patients. In the TD-NSAA subgroup, the ORR was even higher at 88.0% (22/25) with substantial improvements in hematologic parameters and quality of life. Extending treatment from 16 to 24 weeks increased the CR and robust PR rate from 24.0% to 44.0%. The median time to achieve an initial response was 6, and 14 weeks for robust PR. Adverse events occurred in 35% of patients, predominantly Grade 1 or 2 and were manageable. Importantly, no clonal progression to myelodysplastic syndrome or leukemia was observed. These findings support hetrombopag plus CsA as a potential first-line therapeutic intervention for NSAA, especially in TD-NSAA patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhang L, Li R, Liang Q, et al. Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial. Am J Hematol. 2026. PMID: 41489450. doi:10.1002/ajh.70183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。